Latest News

Phase 3 LUCIDITY results showed avexitide reduced Level 2 and Level 3 hypoglycemic events by 55% vs placebo in post-bariatric hypoglycemia.

The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.

Stepped reminders to PCPs and patients increased annual lung cancer screening adherence by 27.7 percentage points, according to new research.

Relationship-based navigation helped more primary care patients access health and social services than referral to a free information service.

The US FDA granted breakthrough device status to Freenome’s investigational blood test designed to triage high-risk adults for lung cancer screening.

The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.

Insulin icodec is now available in the US after FDA approval, offering adults with type 2 diabetes a once-weekly basal insulin option.

Topline phase 2 data showed single-dose ABCL635 reduced moderate-to-severe vasomotor symptom frequency by 83% at week 4.